Comparative efficacy and safety of apixaban and rivaroxaban versus warfarin in atrial fibrillation patients with end-stage renal disease: a systematic review and meta-analysis.

Ren Fail · 2026 · PMC13173575 · PMID 42128628

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The pooled analysis of three RCTs showed apixaban and rivaroxaban were associated with lower risks of SSE (RR 0.50, 95% CI: 0.19–1.35; p = 0.17; I 2 = 0%, Figure 5d ) and all-cause mortality (RR 0.95, 95% CI: 0.74–1.23; p = 0.71; I 2 = 5%, Figure 5e ) compared with warfarin, although these differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.